

Nectar Lifesciences Ltd.



Ref. No.: NLL/CS/2025- WFH

November 13, 2025

To,
National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Symbol: NECLIFE

Scrip Code: 532649

Sub: Disclosure under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")– Completion of Slump Sale and Asset Sale

Ref: Stock exchange intimation vide letter no. NLL/CS/2025- 605 dated November 11, 2025

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations and further to the aforesaid stock exchange intimation relating to the (i) business transfer agreement ("**BTA**") executed between Nectar Lifesciences Limited ("**Company**") and Ceph Lifesciences Private Limited ("**Purchaser**") dated July 07, 2025; and (ii) asset purchase agreement executed between the Company and the Purchaser dated July 07, 2025 ("**APA**"), vide which it was informed that the slump sale and assets have been completed on November 10, 2025.

In this regard, please note:

1. The final consideration under BTA is worked out to INR 1253.99 crore in accordance with the working capital adjustments as specified in the BTA; and
2. The final consideration under APA remained same as INR 20.00 crore as specified in the APA and disclosed earlier.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer